Brain Fingerprints: Cognitive Profiles Distinguish Four Parkinsonian Disorders
A 1,138-patient UK study maps distinct cognitive and psychiatric signatures for PSP, CBS, MSA, and Parkinson's disease to sharpen early diagnosis.
Summary
Researchers analyzed cognitive and neuropsychiatric data from 1,138 people across four parkinsonian disorders in the UK. They found that each condition carries a distinct cognitive fingerprint: frontal executive dysfunction dominates in PSP, visuospatial deficits in CBS, milder memory and executive impairment in MSA, and sleep disturbances most prominently in PD. Apathy was the hallmark neuropsychiatric feature of PSP, while depression and anxiety predominated in CBS. Critically, neuropsychiatric features outperformed cognitive domains in distinguishing between syndromes. Plasma neurofilament light chain correlated with cognitive but not motor severity in PSP. These findings support a bedside diagnostic classifier to improve earlier, more accurate identification of these rapidly progressive and often misdiagnosed conditions.
Detailed Summary
Atypical parkinsonian syndromes (APS)—progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA)—are approximately 20–40 times rarer than Parkinson's disease (PD) and frequently misdiagnosed, often late in their course. Because they progress faster and reduce life expectancy more dramatically than PD, earlier and more accurate diagnosis is urgently needed. Cognitive and neuropsychiatric features are well recognized in PD but have been less systematically compared across all four conditions in a large, harmonized dataset.
This study integrated cross-sectional baseline data from two major UK longitudinal cohorts: PROSPECT-M-UK (seven sites; PSP n=100, CBS n=50, MSA n=53) and Oxford Discovery (PD n=935), totaling 1,138 participants. Cognitive and psychiatric assessments used bedside-applicable screening tools including the Montreal Cognitive Assessment (MoCA), Addenbrooke's Cognitive Examination (ACE-III), and validated neuropsychiatric scales. Data from both cohorts were harmonized and analyzed using multiple linear regression, controlling for age and disease duration. Patients were reclassified according to current MDS diagnostic criteria where applicable.
Five key results emerged. First, each syndrome displayed a distinctive cognitive profile using clinically accessible tools: PSP showed the most prominent frontal-executive dysfunction; CBS showed the greatest visuospatial deficits; MSA showed milder impairments in memory and executive function relative to PD. Second, neuropsychiatric features differentiated syndromes even more reliably than cognitive domains. Apathy was most prominent in PSP, depression and anxiety in CBS, and sleep disturbances in PD. Notably, apathy and impulsivity were positively correlated across all disorders. Third, both cognitive and motor function declined with disease duration, and motor severity predicted cognitive decline in PSP, CBS, and PD—but not in MSA, suggesting that cognitive and motor trajectories are decoupled in MSA. Fourth, plasma neurofilament light chain (NfL) levels, measured in a subset, correlated with cognitive but not motor deficits in PSP, pointing to NfL as a potential cognitive biomarker in this condition. Fifth, cognitive deficits independently contributed to impairment in activities of daily living beyond motor severity: every two-point drop on the MoCA corresponded to a one-point worsening on the Schwab and England Activities of Daily Living scale.
The authors used these findings to construct a diagnostic classifier for in-vivo differentiation of APS, which could support clinicians ahead of anticipated neuroprotective therapies. The work also underscores the functional burden of cognitive impairment independent of motor disability, with direct implications for patient care and caregiver planning.
Important caveats include the cross-sectional design, which limits causal inference, and the relatively small APS group sizes compared to the PD cohort. Clinical diagnoses without neuropathological confirmation introduce some diagnostic uncertainty. Longitudinal cohort studies with post-mortem validation remain essential to fully validate these cognitive and neuropsychiatric biomarkers.
Key Findings
- PSP shows the most pronounced frontal-executive dysfunction; CBS shows the greatest visuospatial deficits among the four syndromes.
- Neuropsychiatric features—apathy in PSP, depression and anxiety in CBS—discriminate syndromes better than cognitive domains alone.
- Motor severity predicts cognitive decline in PSP, CBS, and PD, but not MSA, suggesting decoupled trajectories in MSA.
- Plasma neurofilament light chain correlates with cognitive but not motor deficits specifically in PSP.
- Each two-point MoCA decline worsens daily living scores by one point, independent of motor severity.
Methodology
Cross-sectional analysis of 1,138 participants from two UK cohorts (PROSPECT-M-UK and Oxford Discovery) using harmonized bedside cognitive and neuropsychiatric assessments. Diagnoses were reclassified to current MDS criteria; multiple linear regression controlled for age and disease duration. Plasma NfL was analyzed in a subset of participants.
Study Limitations
The cross-sectional design prevents causal or temporal inferences about cognitive and motor trajectories. APS group sizes (50–100 patients) are substantially smaller than the PD cohort (935), limiting statistical power for subgroup comparisons. Clinical diagnoses lack neuropathological confirmation, introducing potential diagnostic misclassification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: